A citation-based method for searching scientific literature

Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
Times Cited: 109



Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
Times Cited: 367




List of shared articles



Times cited

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein. Heart Fail Rev 2021
11


Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019
48

Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao, Beiyan Bao. Int Urol Nephrol 2019
6

Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review.
Izabela Rodrigues Figueiredo, Sara Cardoso Paes Rose, Nathália Bandeira Freire, Marina Stabile Patrocínio, Natália Pierdoná, Roberto José Bittencourt. Rev Assoc Med Bras (1992) 2019
5

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Mohamed Ibrahim. Sci Rep 2019
4

Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Hui Shao, Suodi Zhai, Dajin Zou, Mohammed Umer Mir, Nadine K Zawadzki, Qian Shi, Shuqian Liu, Lizheng Shi. Curr Med Res Opin 2017
22

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
27


A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
A Avogaro, A Giaccari, P Fioretto, S Genovese, F Purrello, F Giorgino, S Del Prato. Expert Rev Clin Pharmacol 2017
10





SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Huilin Tang, Qi Dai, Weilong Shi, Suodi Zhai, Yiqing Song, Jiali Han. Diabetologia 2017
53


Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Wenying Yang, Ping Han, Kyung-Wan Min, Bei Wang, Traci Mansfield, Caroline T'Joen, Nayyar Iqbal, Eva Johnsson, Agata Ptaszynska. J Diabetes 2016
30


Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Kristina Johnsson, Eva Johnsson, Traci A Mansfield, Yshai Yavin, Agata Ptaszynska, Shamik J Parikh. Postgrad Med 2016
26

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Christian Sonesson, Peter A Johansson, Eva Johnsson, Ingrid Gause-Nilsson. Cardiovasc Diabetol 2016
113

Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Annika Mellander, Martin Billger, Eva Johnsson, Anna Karin Träff, Shigeru Yoshida, Kristina Johnsson. Clin Drug Investig 2016
6


Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016
107


Dapagliflozin in patients with type 2 diabetes mellitus.
Theodosios D Filippatos, Evangelos N Liberopoulos, Moses S Elisaf. Ther Adv Endocrinol Metab 2015
16

Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Jason Powell, Shannon A Miller, James R Taylor. South Med J 2015
7